TriSalus Life Sciences Reports Strong Q1 2025 Growth

Trisalus Life Sciences, Inc. ( (TLSI) ) has released its Q1 earnings. Here is a breakdown of the information Trisalus Life Sciences, Inc. presented to its investors.

TriSalus Life Sciences, Inc. is an oncology-focused medical technology company that integrates innovative delivery technology with standard-of-care therapies, aiming to transform treatment outcomes for patients with solid tumors. The company recently reported its first quarter 2025 financial results, showcasing significant revenue growth and strategic investments.

In the first quarter of 2025, TriSalus Life Sciences achieved a 42% increase in revenue year-over-year, driven by the expanded use of its TriNav system and strategic investments in its core liver market. The company also strengthened its balance sheet with $22 million in gross proceeds from a private placement, which will support further growth initiatives.

Key financial highlights include net sales of $9.2 million, an 84% gross margin, and a reduction in operating losses to $7.3 million compared to the previous year. The company also announced new product launches and expanded reimbursement coverage, which are expected to enhance its market presence and drive future growth.

Looking ahead, TriSalus remains committed to its growth-oriented strategy, confirming its guidance of at least 50% revenue growth for 2025. While the company does not expect to be adjusted EBITDA-positive or cash flow-positive this year due to increased investments, it anticipates achieving positive adjusted EBITDA by the first half of 2026.